Top

EJNMMI Research

Published in:

Open Access 01-12-2011 | Preliminary research

¹⁸F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with ²²³Ra-chloride (Alpharadin)

Authors: Gary JR Cook, Chris Parker, Sue Chua, Bernadette Johnson, Anne-Kirsti Aksnes, Val J Lewington

Published in: EJNMMI Research | Issue 1/2011

Abstract

Background

A qualitative assessment of conventional bone scintigraphy with ^99mTc methylene diphosphonate is perceived as an insensitive method for monitoring the treatment response of bone metastases, and we postulated that semi-quantitative ¹⁸F-fluoride positron emission tomography (PET) might serve as a suitable alternative biomarker of the treatment response.

Methods

Five patients with castrate-resistant prostate cancer and bone metastases with no known soft tissue disease received 100 kBq/kg of radium-223 (²²³Ra)-chloride (Alpharadin) therapy at 0 and 6 weeks and had whole body ¹⁸F-fluoride PET scans at baseline, 6 and 12 weeks with concurrent prostatic-specific antigen (PSA) and alkaline phosphatase (ALP) measurements. A qualitative comparison of the PET scans was performed blinded to the PSA and ALP results. A semi-quantitative comparison was made by measuring the maximum standardised uptake values (SUVmax) in five bone metastases in each patient. The means of the five SUVmax measurements in each subject were used as a quantitative measure of global metastatic activity at each time point.

Results

Three patients showed a PSA decline at 12 weeks (-44%, -31%, -27% reduction) whilst two patients showed PSA increases (+10%, +17%). All five patients showed a reduction in ALP of greater than 25%. The qualitative assessment of the ¹⁸F-fluoride scans recorded a stable disease in each case. However, the semi-quantitative assessment showed agreement with the PSA decline in three patients (-52%, -75%, -49%) and minimal change (+12%, -16%) in two patients with increased PSA at 12 weeks. Four patients showed similar reductions in mean SUVmax and ALP at 12 weeks.

Conclusions

The semi-quantitative ¹⁸F-fluoride PET is more accurate than the qualitative comparison of scans in assessing response in bone metastases, correlating with the PSA response and ALP activity and offering a potential imaging biomarker for monitoring treatment response in bone metastases following treatment with ²²³Ra-chloride.

Available only for authorised users

Prostate cancer - UK incidence statistics [http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/#geog]

Rubens RD: Bone metastases - incidence and complications. In Cancer and the skeleton. Edited by: Rubens RD, Mundy GR. London: Martin Dunitz; 2000:33–42.

Clamp A, Danson S, Nguyen H, Cole D, Clemons M: Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 2004, 5: 607–616. 10.1016/S1470-2045(04)01596-7PubMedCrossRef

Therasse P, Arbuck E, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000, 92: 205–216. 10.1093/jnci/92.3.205PubMedCrossRef

Haywood JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977, 13: 89–94.CrossRef

Coombes RC, Dady P, Parsons C, McCready VR, Ford HT, Gazet JC, Powles TJ: Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer 1983, 52: 610–614. 10.1002/1097-0142(19830815)52:4<610::AID-CNCR2820520406>3.0.CO;2-5PubMedCrossRef

Sundkvist GM, Ahlgren L, Lilja B, Mattsson S, Abrahamsson PA, Wadström LB: Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchidectomy. Eur J Nucl Med 1988, 14: 203–206.PubMedCrossRef

Sundkvist GM, Björk T, Kjellström H, Lilja B: Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues. Scand J Urol Nephrol 1996, 30: 29–32. 10.3109/00365599609182345PubMedCrossRef

Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI: A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res 1998, 4: 1765–1772.PubMed

10.

Rydh A, Ahlström KR, Larsson A, Johansson L, Damber JE, Tomiç R, Hietala SO: Quantitative bone scintigraphy. A methodological evaluation in prostate cancer. Acta Radiol 2000, 41: 183–188. 10.1080/028418500127345028PubMedCrossRef

11.

Condon BR, Buchanan R, Garvie NW, Ackery DM, Fleming J, Taylor D, Hawkes D, Goddard BA: Assessment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imaging. Br J Radiol 1981, 54: 18–23. 10.1259/0007-1285-54-637-18PubMedCrossRef

12.

Blau M, Nagler W, Bender MA: Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962, 3: 332–334.PubMed

13.

Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Träger H, Nüssle K, Reske SN: Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus ¹⁸ F PET. J Nucl Med 1999, 40: 1623–1629.PubMed

14.

Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, Messer P, Nüssle K, Elsner K, Glatting G, Träger H, Neumaier B, Diederichs C, Reske SN: Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and PET. J Clin Oncol 1999, 17: 2381–2389.PubMed

15.

Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, Dziuk K, Gabelmann A, Reske SN, Hetzel M: Evaluation of the clinical value of planar bone scans, SPECT and ¹⁸ F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001, 42: 1800–1804.PubMed

16.

Kruger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, Wibmer T, Merk T, Hombach V, Reske SN: Detection of bone metastases in patients with lung cancer: 99mTc MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET-CT. Eur J Nucl Med Mol Imaging 2009, 36: 1807–1812. 10.1007/s00259-009-1181-2PubMedCrossRef

17.

Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I: The detection of bone metastases in patients with high risk prostate cancer: ^99m Tc MDP planar bone scintigraphy, single and multi field of view SPECT, ¹⁸ F-fluoride PET and ¹⁸ F-fluoride PET/CT. J Nucl Med 2006, 47: 287–297.PubMed

18.

Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E: Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004, 45: 272–278.PubMed

19.

Uchida K, Nakajima H, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, Tsuchida T, Okazawa H, Fujibayashi Y, Baba H: Effects of Alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by ¹⁸ F-fluoride PET: a prospective study. J Nucl Med 2009, 50: 1808–1814. 10.2967/jnumed.109.062570PubMedCrossRef

20.

Blake GM, Park-Holohan SJ, Cook GJR, Fogelman I: Quantitative studies of bone with the use of ¹⁸ F-fluoride and ^99m Tc-methylene diphosphonate. Semin Nucl Med 2001, 31: 28–49. 10.1053/snuc.2001.18742PubMedCrossRef

21.

Wade AA, Scott JA, Kuter I, Fischman AJ: Flare response in ¹⁸ F-fluoride ion PET bone scanning. AJR 2006, 186: 1783–1786. 10.2214/AJR.05.0225PubMedCrossRef

22.

Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I: Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 1988, 29: 1354–1359.PubMed

Title: 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)
Authors: Gary JR Cook
Chris Parker
Sue Chua
Bernadette Johnson
Anne-Kirsti Aksnes
Val J Lewington
Publication date: 01-12-2011
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2011
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/2191-219X-1-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with ²²³Ra-chloride (Alpharadin)

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Evaluation of 18F-nifene binding to α4β2 nicotinic receptors in the rat brain using microPET imaging

Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets

Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects

White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism

Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors